Cantor Fitzgerald raised the price target for the Mereo BioPharma Group plc (NASDAQ:MREO) stock to “an Overweight”. The rating was released on August 12, 2022, according to finviz. The research report from Needham has initiated the stock to Buy, with a price target set at $10.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Mereo BioPharma Group plc (NASDAQ:MREO) raised 5.15% to close Monday’s market session at $1.02, higher as compared to yesterday’s close. The stock price fluctuated between $0.902 and $1.17 throughout the trading session with the volume trading being 2325531 shares, which represented a significant variation when compared to the three months average volume of 641.87K shares. The firm’s stock price fluctuated 14.90% within the last five trades and 92.45% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -34.62% in the last 6 months and 4.51% was added to its value over the previous 3 months. MREO stock is trading at a margin of 33.68%, 33.91% and 8.99% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, MREO deals in the Healthcare domain. The stock is trading -44.86 percent below its 52-week high and 238.87 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -49.6. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Mereo BioPharma Group plc’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $127.49 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for Mereo BioPharma Group plc (NASDAQ:MREO) is 9.27. The firm managed a Price-to-Book ratio of 1.71, which equates the market value of a stock with its book value.